Cardiome slashes 85 per cent of workers after Merck ends development efforts

VANCOUVER – Cardiome Pharma Corp. (TSX:COM) is cutting 85 per cent of its workers as it eliminates all of those focused on internal research and certain support functions. The move comes after Merck terminated development efforts relating to the vernakalant oral program.

News from © iNFOnews.ca, . All rights reserved.
This material may not be published, broadcast, rewritten or redistributed.